A Study of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension – CATALYST 2018-11-09T16:06:31+00:00

Clinical Trials

June 14, 2017

A Study of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension – CATALYST

  • Study Sponsor: Reata Pharmaceuticals, Inc.
  • Institution: Reata Pharmaceuticals
  • Start Date: Thursday, September 29, 2016
  • End Date: Friday, November 1, 2019
  • Design: Placebo-controlled
    Background treatment allowed
  • Age range (years): from 18 to 75
  • Type of PH
    • All PH
    • All PAH (Group 1 PH)
    • CTD – APAH
    • Pulmonary Arterial Hypertension (PAH)
  • Study Duration for individual patient: 28 weeks
  • Contact: www.CATALYSTtrial.com
  • Listing on clinicaltrials.gov